Compare Novo Nordisk A/S (NVO) vs Global X NASDAQ 100 Covered Call ETF (QYLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Global X NASDAQ 100 Covered Call ETF — how do they compare? Novo Nordisk A/S trades at $38.63 (market cap $165.31B), while Global X NASDAQ 100 Covered Call ETF trades at $18.69 (market cap $8.49B). The key difference: Novo Nordisk A/S is far larger — about 19.5× Global X NASDAQ 100 Covered Call ETF's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Global X NASDAQ 100 Covered Call ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Global X NASDAQ 100 Covered Call ETF for 51 Days on average.
| NVO | QYLD | |
|---|---|---|
Market Cap | $165.31B | $8.49B |
Volume | 11,432,838 | 2,913,938 |
Sector | Health | Income / Options Overlay |
52-Week High | $63.98 | $18.68 |
52-Week Low | $35.29 | $16.70 |
Typical Hold Time | 116 Days | 51 Days |
Enterprise Value | $179.56B | — |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.64, up 0.99% with bearish technical signals despite strong fundamentals. The company maintains exceptional profitability with 35.35% net margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights pipeline developments including weight-loss drug advancements and a $4 billion licensing deal expansion.
While facing competitive pressure in obesity treatments, NVO's valuation remains attractive with a 9.66 P/E ratio. Analyst consensus is bullish with a $44.67 price target, representing 15.6% upside potential. Key risks include FDA regulatory delays and intensifying competition from Eli Lilly in the GLP-1 market.
QYLD trades at $18.685 with minimal daily movement (+0.03%), showing technical bullish signals from moving averages but bearish oscillator readings including overbought RSI levels. The ETF maintains consistent monthly dividend distributions of $0.18 per share, though recent news highlights concerns about declining option premiums and long-term capital erosion despite the attractive yield.
The outlook remains cautious as covered call strategies limit upside participation during market rallies. While providing reliable income, QYLD faces structural headwinds including capped growth potential and potential tax reclassification of distributions. Investors should weigh the trade-off between high current yield and long-term total return potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Global X NASDAQ 100 Covered Call ETF
QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →
